Cargando…
Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus
The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to include antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use o...
Autores principales: | Al-Beltagi, Sarah, Preda, Cristian Alexandru, Goulding, Leah V., James, Joe, Pu, Juan, Skinner, Paul, Jiang, Zhimin, Wang, Belinda Lei, Yang, Jiayun, Banyard, Ashley C., Mellits, Kenneth H., Gershkovich, Pavel, Hayes, Christopher J., Nguyen-Van-Tam, Jonathan, Brown, Ian H., Liu, Jinhua, Chang, Kin-Chow |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7913267/ https://www.ncbi.nlm.nih.gov/pubmed/33546185 http://dx.doi.org/10.3390/v13020234 |
Ejemplares similares
-
Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin
por: Al-Beltagi, Sarah, et al.
Publicado: (2021) -
Thapsigargin at Non-Cytotoxic Levels Induces a Potent Host Antiviral Response that Blocks Influenza A Virus Replication
por: Goulding, Leah V., et al.
Publicado: (2020) -
Respiratory Syncytial Virus
por: Fraire, Armando E., et al.
Publicado: (2013) -
Respiratory syncytial virus
por: Ruuskanen, Olli, et al.
Publicado: (1993) -
Respiratory syncytial virus
por: Munoz, Flor M., et al.
Publicado: (2020)